1998
|
|
Sinai Center for Thrombosis Research - Founded by Paul A. Gurbel, M.D. |
2003
|
|
Dr, Gurbel is the first researcher to discover that clopidogrel (Plavix)
was not working in approximately 30% of patients, exposing a major limitation of
one of the top selling drugs in the world. |
2007
|
|
Dr. Gurbel and his team then prove that patients who had undergone coronary
stenting and were non-responsive to clopidogrel (Plavix) had a significant
increased risk for a serious cardiac event. |
2008
|
|
Research by Dr. Gurbel and his team helps shape treatment guidelines for the
dosage of anti-platelet drugs for the American Heart Association and the
American College of Cardiology. |
2009
|
|
Dr. Gurbel serves as the senior investigator for a study that identified a common
gene variant, CYP2C19*2, carried by about 30% of the general population, that
plays a major role in determining response to clopidogrel (Plavix) and risk for
subsequent cardiac events after coronary artery stenting. Results of this study
are published in the Journal of the American Medical Association. |
2010
|
|
Research by Dr. Gurbel and his team shows that new anti-platelet agent,
ticagrelor, works in clopidogrel (Plavix) non-responders, representing a promising
new treatment option. |
2011
|
|
Research by Dr. Gurbel and his team plays a pivotal role in FDA approval of
ticagrelor, which is marketed under the brand name Brilinta by AsrtaZeneca. |
2012
|
|
Circulation publishes findings of Dr. Gurbel and his team - “Platelet Function
Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-
Treated Patients Undergoing Coronary Artery Bypass Graft Surgery: The Timing
Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding
Related to CABG (TARGET-CABG) Study.” |
2012
|
|
The Journal of the American Medical Association publishes an editorial by Dr. Gurbel &
his team entitled “Clopidogrel Efficacy and Cigarette Smoking Status.” |